Editorial Videos

Rob DeWig, Vice President of Healthcare Sales, Inmar, touches on the impact of Inmar and Premier's expanded agreement on the broader healthcare and pharmacy ecosystems.

Ryan Quigley, CEO of Inizio, discusses how his experience as Chief Operating Officer shaped his journey to CEO.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos transforms clinical practice by establishing the first FDA-approved standard of care for recurrent respiratory papillomatosis (RRP), shifting treatment from repeated surgeries to an immunotherapy that addresses the root HPV infection, with future plans to expand into pediatric populations and redosing strategies.

Helen Sabzevari, PhD, president and CEO of Precigen, reflects on how Papzimeos sets an important precedent for rare disease therapies, with its broad FDA label for all adult patients with recurrent respiratory papillomatosis (RRP) highlighting the potential for earlier intervention to prevent irreversible damage and establish new standards of care.

Helen Sabzevari, PhD, president and CEO of Precigen, discusses the FDA’s decision to grant full approval to Papzimeos without requiring a confirmatory trial, highlighting how strong safety, efficacy, and durability data supported a broad label for all adult patients with recurrent respiratory papillomatosis (RRP).

Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos, developed using the company’s AdenoVerse platform, became the first FDA-approved therapy for adult patients with recurrent respiratory papillomatosi.

In this video interview, Helen Sabzevari, PhD, president and CEO of Precigen, discusses the background of Recurrent Respiratory Papillomatosis treatments that led to Papzimeos becoming the first FDA-approved therapy for Recurrent Respiratory Papillomatosis.

In today’s Pharmaceutical Executive Daily, we review the wave of pharmaceutical layoffs shaping 2025, highlight the latest Pharm Exec Top 50 company rankings, and cover BioNTech and Duality Biologics’ clinical trial success with BNT323.

Marc Stapley, CEO of Veracyte, explains how investors are reacting to recent advancements in cancer care.

Noah Nasser discusses how data silos cause complications with researchers.

Marc Stapley, CEO of Veracyte, discusses the importance of ongoing evidence collection.

Noah Nasser discusses how new technologies are changing the data landscape.

Marc Stapley, CEO of Veracyte, discusses new approaches to diagnostics and how its transforming cancer care.

Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about leveraging point-of-care marketing momentum and its influence on decision making and how does Doceree maintain contextual relevance in marketing on a national scale.

Noah Nasser discusses one of the most critical components of working with RWD.

Michael Grosberg discusses the issues that need to be addressed to bring drug prices down for patients.

Derrick Gastineau discusses the importance of finding the right spaces to ensure patients see accurate information about medications.

Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about the role of AI in programmatic marketing, and the expectations of developments in communication between healthcare professionals and pharmaceutical brands.

Derrick Gastineau discusses the importance of patients’ hearing stories from other patients.

Noah Nasser discusses the importance of keeping data still.

With insured patients less likely to benefit, who actually does benefit from D2C?

Derrick Gastineau discusses how the focus on weight loss medications has shifted in recent years.

Shiladitya Sengupta, founder, Vyome Therapeutics, explains how the company’s strong ties in India’s biotech and healthcare sectors are helping to create innovative solutions for global markets.

Michael Grosberg discusses how people with insurance will be impacted by D2C drug sales.

Rob Abbott, CEO, ISPOR, highlights how uniting regulators, payers, and academic leaders worldwide can accelerate access to innovative treatments and strengthen evidence-based healthcare.

Ron Lanton, partner, Lanton Law, warns that ongoing lawsuits targeting vaccine policy could create ripple effects across FDA decision-making and reshape how future emergency use authorizations are granted.

Ron Lanton, partner, Lanton Law, warns that recent changes to federal vaccine recommendations could trigger extensive litigation as insurers, providers, and patients face new access and coverage challenges.